Clinical trial
A Phase 2 Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma at Stanford University
NCT00854620 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma at Stanford University
- Lead sponsor
- Stanford University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- January 31, 2011
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, renal cell, kidney cancer, kidney disease